Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 3:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,102 matching trials from the live ClinicalTrials.gov search.
Conditions
Blood Loss, Surgical, Postoperative Hemorrhage
Interventions
Trasylol (Aprotinin, BAYA0128), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
18
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 14 more
Conditions
Non-muscle Invasive Bladder Cancer
Interventions
eRapa, Placebos
Drug
Lead sponsor
Robert Svatek
Other
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Dallas, Texas • San Antonio, Texas
Completed Not applicable Interventional Results available

Acceptability of Less Harmful Alternatives to Cigarettes

NCT00957424
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
telephone-based intervention, nicotine replacement therapy, informational intervention, internet-based intervention, questionnaire administration
Behavioral · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme, Cholangiocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Epithelial Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma, Gastric Adenocarcinoma, Malignant Mesothelioma (MM), Von Hippel Lindau, Bladder Cancer, Bladder Urothelial Carcinoma
Interventions
89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
Diagnostic Test
Lead sponsor
Telix Pharmaceuticals (Innovations) Pty Ltd
Industry
Eligibility
18 Years to 95 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
10
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 7 more
Conditions
Bladder Cancer
Interventions
Pembrolizumab, Gemcitabine, Cisplatin, Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND]), Placebo
Drug · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
907 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
24
States / cities
La Jolla, California • Santa Monica, California • Washington D.C., District of Columbia + 21 more
Conditions
Bladder Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Recruiting Not applicable Interventional

Image-Guided Gynecologic Brachytherapy

NCT02993900
Conditions
Cervical Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer, Bladder Cancer
Interventions
Image-Guided Brachytherapy
Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Bladder Neoplasm, Neoplasm Recurrence, Local, Transitional Cell, Carcinoma, Carcinoma in Situ, Mycobacterium
Interventions
EN3348, Mitomycin C
Biological
Lead sponsor
Bioniche Life Sciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
56
States / cities
Anchorage, Alaska • Phoenix, Arizona • Tucson, Arizona + 49 more
Conditions
Malignant Neoplasms of Urinary Tract
Interventions
Arginine recovery supplement, Omega-3 Fatty Acids
Drug · Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Conditions
Cancer
Interventions
monoclonal antibody RAV12
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Miami, Florida + 2 more
Conditions
Breast Cancer, Cervical Cancer, Bladder Cancer, Colorectal Cancer, Endometrial Cancer, Lung Cancer, Prostate Cancer
Interventions
Physical Activity Promotion Intervention
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Bladder Cancer
Interventions
cisplatin, fluorouracil, paclitaxel, radiation therapy, Gemcitabine, Radical cystectomy
Drug · Radiation · Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Up to 120 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2018
U.S. locations
2
States / cities
Salt Lake City, Utah
Conditions
Bladder Cancer
Interventions
Paclitaxel, Carboplatin, Gemcitabine
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Transitional Cell Carcinoma of the Bladder, Ureter Cancer
Interventions
arsenic trioxide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Metastatic Urothelial Carcinoma, Urothelial Cancer, Urothelial Carcinoma, Locally Advanced or Metastatic Urothelial Carcinoma, Bladder Cancer, Bladder Neoplasms, Bladder Tumors, Cancer of Bladder, Cancer of the Bladder, Malignant Tumor of Urinary Bladder, Neoplasms, Bladder, Urinary Bladder Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
5,122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Conditions
Muscle Invasive Bladder Cancer (MIBC)
Interventions
ctDNA testing
Diagnostic Test
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Muscle Invasive Bladder Cancer
Interventions
APL-1202 in combination with tislelizumab, Tislelizumab alone
Drug
Lead sponsor
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Bladder Cancer
Interventions
Apaziquone, Placebo
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
28
States / cities
Glendale, Arizona • Phoenix, Arizona • Laguna Woods, California + 24 more
Conditions
Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer, Hepatocellular Cancer, Bladder Cancer, Sarcoma, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Squamous Cell Carcinoma
Interventions
PF-07263689, Sasanlimab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Duarte, California • New York, New York
Conditions
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer, Melanoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Merkel Cell Carcinoma, GastroEsophageal Cancer, Renal Cell Carcinoma, Castration-resistant Prostate Cancer
Interventions
Etrumadenant, Zimberelimab
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
12
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 8 more
Active, not recruiting Early Phase 1 Interventional

Bladder Preservation or Cystectomy for MIBC

NCT07821177
Conditions
Muscle-Invasive Bladder Carcinoma, Bladder Cancer, Urothelial Carcinoma
Interventions
Gemzar, Cisplatin, Adrucil, Mitomycin, Radical Cystectomy
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Bladder Adenocarcinoma, Bladder Squamous Cell Carcinoma, Bladder Urothelial Carcinoma, Recurrent Bladder Carcinoma, Stage I Bladder Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer
Interventions
Recombinant Fowlpox-TRICOM Vaccine, Recombinant Fowlpox GM-CSF Vaccine Adjuvant, Therapeutic Conventional Surgery, Pharmacological Study, Laboratory Biomarker Analysis
Biological · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Transitional Cell Carcinoma of the Bladder
Interventions
Gemcitabine, Cisplatin, Sunitinib Malate, Radical Cystectomy
Drug · Procedure
Lead sponsor
Noah Hahn, M.D.
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Gainesville, Florida • Indianapolis, Indiana • South Bend, Indiana + 1 more
Conditions
Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Unresectable Urothelial Carcinoma
Interventions
Bevacizumab, Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Placebo Administration
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
872
States / cities
Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 529 more